Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
According to ICMR, the upgraded OmiSure RT-PCR test for Covid-19 successfully detects all sub-types of Omicron that are currently prevalent in India
Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice
Previously, the use of the drug was limited to patients requiring hospitalization
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Narayanan to lead SeQuent through next phase of consolidation and growth
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Subscribe To Our Newsletter & Stay Updated
